Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (6): 1023-1030    DOI: 10.31083/j.ejgo.2020.06.5369
Original Research Previous articles | Next articles
Validation of a treatment-selection rule for patients with advanced stage ovarian cancer
R. van de Vrie, 1, *(), E. van Werkhoven, 2, M. J. Rutten1, J. D. Asseler1, H. S. van Meurs1, D. E. Werter1, M. R. Buist1, A.H. Zwinderman3, C. A. R. Lok4, P.M.M. Bossuyt2, G. G. Kenter1, P. Tajik2, 5
1Department of Obstetrics and Gynaecology, Centre for Gynaecologic Oncology Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
2Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands
3Department of Epidemiology, Biostatistics & Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
4Department of Gynaecologic Oncology, Centre for Gynaecologic Oncology Amsterdam, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
5Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
Download:  PDF(512KB)  ( 57 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of investigation: To externally validate the rule of Van Meurs et al. for selecting patients with advanced epithelial ovarian cancer for treatment with primary surgery or neoadjuvant chemotherapy (NACT). Materials and Methods: We analysed a historical cohort of 900 consecutive patients with FIGO stage IIIC/IV ovarian cancer treated for advanced stage epithelial ovarian cancer at the Centre of Gynaecologic Oncology Amsterdam between 1998 and 2012. To externally validate the treatment-selection rule of Van Meurs et al. four groups were defined based on metastatic tumour size (smaller or larger than 45 mm) and FIGO stage (IIIC vs. IV). Within these groups, we compared survival outcomes of primary surgery and NACT. Results: Differential treatment benefit in model-defined subgroups based on metastatic tumour size and FIGO stage was confirmed (interaction p = 0.008). Survival after primary surgery was significantly better compared to NACT plus interval debulking surgery for patients in FIGO stage IIIC (p = 0.001) or IV (p = 0.028) with metastases ≤ 45 mm, and those in FIGO stage IIIC with metastases > 45 mm (p = 0.011). Survival was not significantly worse for FIGO stage IV patients with metastases > 45 mm (p = 0.094). In patients with such large metastases, the location (omentum versus elsewhere in the body) was not prognostic (p = 0.44). Conclusion: Our study has externally validated the treatment-selection rule first described by van Meurs et al. Primary surgery was shown to be superior for all patients except for the FIGO stage IV patients with a large metastatic tumour size (> 45 mm), irrespective of localisation of the metastasis.
Key words:  Ovarian cancer      Treatment strategy      Overall survival      FIGO stage      Metastasis     
Submitted:  29 January 2019      Accepted:  10 May 2020      Published:  15 December 2020     
Fund: AXA Research Fund
*Corresponding Author(s):  ROELIEN VAN DE VRIE     E-mail:  r.vandevrie@amsterdamumc.nl
About author:  Contributed equally.

Cite this article: 

R van de Vrie, E van Werkhoven, M J Rutten, J D Asseler, H S van Meurs, D E Werter, M R Buist, A.H. Zwinderman, C A R Lok, P.M.M. Bossuyt, G G Kenter, P Tajik. Validation of a treatment-selection rule for patients with advanced stage ovarian cancer. European Journal of Gynaecological Oncology, 2020, 41(6): 1023-1030.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.06.5369     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I6/1023

[1] Francesco Plotti, Bartolone Martina, Terranova Corrado, Luvero Daniela, Scaletta Giuseppe, Gatti Alessandra, Benedetti Panici Pierluigi, Angioli Roberto. Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 889-896.
[2] Qing-Hui Kan, Ying-Lin Wang, Mei-Ling Xu, Fu-Yun Tong, Yong-Sheng Shi. Network meta-analysis of targeted drugs in combination with chemotherapy for advanced/metastatic triple-negative breast cancer treatment[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 897-905.
[3] Irina Esteves-Krasteva, José Ángel Minguez, José María Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Gabriel Zozaya-Larequi, Juan Luis Alcázar, Matías Jurado. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 906-912.
[4] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[5] Haci Ozturk Sahin, Zelal Aydin, Ibrahim Ugras Toktas, Cetin Toraman, Ilkbal Temel Yuksel, Alper Seyhan, Ozgur Akbayir. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 924-930.
[6] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta, Miwa Yasaka, Hiroko Machida, Masae Ikeda, Masako Shida, Takeshi Hirasawa, Mikio Mikami. Usefulness of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery, a case control observational study in a single institute in Japan[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 960-968.
[7] Fatih Kose, Songül Alemdaroğlu, Hüseyin Mertsoylu, Ali Ayberk Beşen, Ozan Cem Güler, Seda Yüksel Şimşek, Gürcan Erbay, Cem Önal, Hüsnü Çelik. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 989-995.
[8] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[9] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[10] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[11] Špela Smrkolj, Snježana Frković Grazio, Renata Košir Pogačnik. Endocervical adenocarcinoma in situ with ovarian metastasis: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 802-805.
[12] Qihua Yi, Lin Chen, Sijing Chen, Ying Zheng. Criteria for predicting ovarian metastasis in early-stage cervical adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 726-731.
[13] Dongdong Zhang, Bingdong Zhu, Yajie Fu, Yin Han, Yufeng Wang, Xiaoyun Chen, Lang Zhang, Xiangwen Liu, Ying Zhang, Yuzhen Guo, Huiling Liu. Downregulation of α-enolase (ENO1) Inhibits Growth, Invasion, and Metastasis of Human Cervical Cancer Cells[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 762-768.
[14] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[15] Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.
No Suggested Reading articles found!